What the research found
This isn't a research study—it's an interview with Wei-Wu He, CEO of Human Longevity Inc. (HLI), a precision medicine company founded in 2013. He discusses the company's trajectory: it began with an ambitious vision to use genomic data combined with detailed phenotypic measurements (whole-body MRI, proteomics, metabolomics) to predict and prevent major age-related diseases. Early execution was unfocused, with the company pursuing multiple directions simultaneously while spending heavily. He took over in 2019, restructured operations, and refocused on accumulating longitudinal health data from thousands of individuals to build predictive algorithms. HLI is now returning to its original scientific mission through collaborations and, according to He, has assembled 13 years of follow-up data from over 10,000 people.
The core thesis remains data-driven: if you can delay major diseases like heart attack, stroke, cancer, and dementia by 20–30 years, lifespan extension follows. He frames this as distinct from luxury wellness services, emphasizing peer-reviewed research and algorithmic development as HLI's differentiators.
Why it matters for you
If you're already tracking biomarkers and optimizing your health protocol, HLI's approach echoes what many MyKine users are doing informally: integrating multiple data streams (genetic background, blood work, imaging, metabolic markers) to make personalized decisions. The company's longitudinal dataset may eventually produce validated algorithms that connect your genome and current phenotype to disease risk in ways individual-level tracking cannot.
For now, the practical implication is modest: HLI offers whole-genome sequencing at lower cost than it did ten years ago, and the company is building models that link genotype to modifiable health outcomes. Whether those models will outperform existing risk scores or your own protocol adherence remains unclear at this stage. He's also acknowledging that precision medicine platforms take time to mature—a useful counterpoint to the hype cycle around AI and longevity.
Caveats
- Interview, not data: This is a CEO's perspective, not independent research validation. No peer-reviewed results are presented.
- No efficacy claims tested here: He describes intent and data holdings, not clinical outcomes. Whether HLI's algorithms actually delay disease better than standard care is unstated.
- Commercial interest: He has substantial personal and financial stake in the company's success.
- Longitudinal data ≠ causal insight: Thirteen years of follow-up is valuable, but correlation between biomarkers and outcomes doesn't prove intervention will work.
- "Eventually democratized": Current access remains restricted to high-net-worth clients at substantial cost. Timelines for broader availability are not specified.